Opdivo plus Yervoy meets in Phase III for first-line NSCLC with high tumor mutation burden

Bristol-Myers Squibb Co. (NYSE:BMY) said first-line treatment with Opdivo nivolumab plus Yervoy ipilimumab met the co-primary endpoint of improving progression-free survival (PFS) vs. platinum-doublet chemotherapy in advanced non-small cell lung cancer (NSCLC) patients with high tumor mutation burden, regardless of PD-L1 expression, in Part 1 of the Phase III CheckMate -227 trial.

Details were not disclosed. Tumor mutation burden in CheckMate -227 was assessed using the FoundationOne CDx assay from Foundation Medicine Inc. (NASDAQ:FMI), with high tumor mutation burden defined as at least 10 mutations/megabase...